Chimeric antigen receptor T cell persistence and memory cell formation.

Immunol Cell Biol

Department of Microbiology and Immunology, University of Otago, Dunedin, 9054, New Zealand.

Published: August 2019

It is now becoming clear that less differentiated naive and memory T cells are superior to effector T cells in the transfer of immunity for adoptive cell therapy. This review will outline the challenges faced by chimeric antigen receptor (CAR) T cell therapy in the generation of persistence and memory for CAR T cells, and summarize recent strategies to improve CAR T cell persistence, with a focus on memory cell formation. The relevance of enhancing persistence in more differentiated effector T cells is also covered, because genetic and pharmacological interventions may prolong effector T cell activity and lifespan, thereby improving anti-cancer activity. In particular, it may be possible to enforce epigenetic changes in differentiated T cells to enhance memory CAR T cell formation. Optimizing the generation of self-renewing T cell populations (e.g. memory cells), while maintaining differentiated effector T cells through epigenome modification, will help overcome barriers to T cell expansion and survival, thereby improving clinical outcomes in CAR T cell therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1111/imcb.12254DOI Listing

Publication Analysis

Top Keywords

car t cell
16
effector cells
12
chimeric antigen
8
antigen receptor
8
persistence memory
8
memory cell
8
cell formation
8
memory cells
8
t cell therapy
8
memory car
8

Similar Publications

Messenger ribonucleic acid (mRNA) therapeutics are attracting attention as promising tools in cancer immunotherapy due to their ability to leverage the in vivo expression of all known protein sequences. Even small amounts of mRNA can have a powerful effect on cancer vaccines by promoting the synthesis of tumor-specific antigens (TSA) or tumor-associated antigens (TAA) by antigen-presenting cells (APC). These antigens are then presented to T cells, eliciting strong antitumor immune stimulation.

View Article and Find Full Text PDF

Quantitative pharmacology of dual-targeted bicistronic CAR-T-cell therapy using multiscale mechanistic modeling.

CPT Pharmacometrics Syst Pharmacol

November 2024

Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.

Despite the initial success of single-targeted chimeric-antigen receptor (CAR) T-cell therapy in hematological malignancies, its long-term effectiveness is often hindered by antigen heterogeneity and escape. As a result, there is a growing interest in cell therapies targeting multiple antigens (≥2). However, the dose-exposure-response relationship and specific factors influencing the pharmacology of dual-targeted CAR-T-cell therapy remain unclear.

View Article and Find Full Text PDF

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy and have enhanced the survival of patients with malignant tumors. However, the overall efficacy of ICIs remains unsatisfactory and is faced with two major concerns of resistance development and occurrence of immune-related adverse events (irAEs). Bispecific antibodies (bsAbs) have emerged as promising strategies with unique mechanisms of action to achieve a better efficacy and safety than monoclonal antibodies (mAbs) or even their combination.

View Article and Find Full Text PDF
Article Synopsis
  • CAR T-cell therapies have been effective for blood cancers but face challenges in treating solid tumors; CAR-macrophages (CAR-M) are being explored as an alternative therapy.*
  • CAR-M can be activated and target tumors using tumor-associated antigens, but the mechanisms of their movement and infiltration in tumors are not fully understood.*
  • This study uses a 3D tumor spheroid model created from self-assembling nucleic acid nanostructures to evaluate CAR-M's effectiveness, showing better invasion and tumor-killing abilities compared to traditional 2D models.*
View Article and Find Full Text PDF
Article Synopsis
  • - Pancreatic cancer is a tough-to-treat disease with only a 13% survival rate over five years, and current immunotherapies like CAR T cells aren't very effective for it.
  • - Researchers identified Muc16CD as a new target (tumor-associated antigen) that CAR T cells can attack, which is present in pancreatic tumors.
  • - Muc16CD-targeted CAR T cells show promise in laboratory models, effectively recognizing pancreatic tumor cells and improving tumor control and survival rates.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!